Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.
Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).
At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Patients diagnosed with acute ischemic stroke or transient ischemic attack.
Time from onset to enrollment ≤ 14 days.
Presence of at least one modifiable risk factor (hypertension, diabetes).
Disqualifiers
Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials.
Patients or family members who refuse to sign the informed consent form.
Pregnant or breastfeeding women.
Trial design
Treatments tested in this trial
- Cerebrovascular Disease Secondary Prevention Smart Management System
Treatment groups
4,490 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Collaborator
Xiangya Hospital of Zhongnan University
Collaborator
The affiliated Hospital of Shihezi University
Collaborator
The First Hospital of Jilin University
Collaborator
First People's Hospital of Foshan
Collaborator
The Second Affiliated Hospital of Fujian Medical University
Collaborator
BOE Technology Group Co., Ltd.
Collaborator
Source ClinicalTrials.gov